Updates on BCMA-Targeting Bispecifics in MM

EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma

EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 3.Advances in the Treatment of High-Risk MM

EP: 4.Role of Transplant and MRD in Newly Diagnosed MM

EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM

EP: 6.Treatment of Multiple Myeloma at Early Relapse

EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse

Now Viewing

EP: 8.Updates on BCMA-Targeting Bispecifics in MM

EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma

EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on B-cell maturation antigen (BCMA)–targeted bispecific antibodies teclistamab and elranatamab for relapsed/refractory multiple myeloma (MM). Longer follow-up data suggests improved depth of response over time, especially with elranatamab. Differences in study populations make direct comparisons challenging, but additional BCMA bispecifics are in development.

With multiple approved BCMA-directed therapies now available in later lines (chimeric antigen receptor [CAR] T-cell therapies and 3 bispecific antibodies), treatment selection involves assessing patient and disease factors like pace of progression, logistics, and access issues. CAR T-cell therapy requires coordinating manufacturing and delivery, suiting patients with slower-progressing disease, while bispecific antibodies can be used urgently like in renal failure from hypercalcemia. Real-world data in patients ineligible for registration trials confirms bispecific antibody safety and efficacy in broader populations. Overall, having multiple BCMA options now provides flexibility based on clinical scenarios.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.